近亿元人民币，中博聚力再次领投恩泽康泰B轮融资，外泌体赛道再升温

Core Insights - Enze Kangtai is a leading company in the exosome field, recognized as a national-level "specialized and innovative" small giant in China, with a strong competitive advantage in various business scenarios [1][2] - The company has established a comprehensive professional team focused on exosome research, industrial transformation, and application promotion, with significant collaborations and a healthy financial outlook [2][16] - The exosome market is rapidly growing, particularly in regenerative medicine, with significant advantages over other technologies, driving its commercialization and industrialization [9][14] Company Overview - Founded by Kong Guanyi in 2017, Enze Kangtai has developed a robust foundation in exosome research, with over 3,000 square meters of GMP laboratories and more than 500 key partnerships [1][2] - The company has achieved significant milestones, including the establishment of the first postdoctoral research station and the first expert consensus in the exosome field [2][11] - Enze Kangtai's cash flow is expected to turn positive in the second half of 2024, with a projected break-even by 2025 [2] Exosome Technology and Applications - Exosomes are nano-sized vesicles that facilitate intercellular communication, containing bioactive molecules such as proteins and nucleic acids, making them crucial for targeted drug delivery and disease treatment [4][5][7] - The global exosome market is projected to exceed $10 billion by 2030, with a compound annual growth rate (CAGR) of approximately 32.7% over the next five years [9][14] - Enze Kangtai has developed three major platforms for exosome research and application, focusing on multi-omics analysis, engineering, and large-scale production [11][12] Business Segments - Enze Kangtai operates three main business segments: exosome services, exosome raw materials, and exosome therapies [14] - The exosome service segment is the foundation of the business, providing analysis services and tools for research and early drug development [14] - The exosome raw material segment is expected to grow rapidly, as Enze Kangtai is the first company in China to offer GMP-grade exosome raw materials [14] - The exosome therapy segment is in its early stages but is anticipated to have significant potential in regenerative medicine over the next 3-5 years [14] Market Trends and Future Outlook - The Asia-Pacific regenerative medicine market is expected to grow at a CAGR of 47.2% from 2023 to 2027, surpassing Europe to become the second-largest market globally [9] - Enze Kangtai is well-positioned to capitalize on the regulatory framework for exosome products, which will align them with innovative drug standards by June 2025 [9][16] - The company is supported by strategic investments from Zhongbo Juliy, which aims to enhance its business model and governance while fostering collaboration in the exosome industry [16]